The most advanced of all the malaria vaccine candidates is SPf66 (94,95). It is a synthetic polypeptide. The peptide represents several protective epitopes correlated to several proteins of the pre-erythrocytic and asexual blood stage of P/asmodmn falciporum. Extensive clinical trials with this vaccine have been carried out in South America and Africa (95—97). The efficacy of the vaccine varied in different regions, and generally lower than expected in a developed country. Consequendy, the general appHcation of the vaccine still generates much debate (98). However, this vaccine represents a major advance in the development of a malaria vaccine.  [c.360]

M. Gerecke, J. P. Zimmermann, W. Aschwanden, Helv. Chim. Acta, 53, 991 (1970).  [c.34]

Although a broad range of P-lactamase inhibitors has been discovered, only clavulanic acid and sulbactam have been commercialized. Clavulanic acid (12, R = CH2OH, R = H), manufactured by SmithKlinp Beecham, is sold as an oral and parenteral product in combination with amoxicillin under the trade name Augmentin. A parenteral product in combination with ticarcillin [34787-01-4], C25H2gN20 S, has the trade name, Timentin. In 1990 worldwide sales of clavulanic acid containing products were about 725 million.  [c.56]

Ampicillin and its congeners amoxicillin, bacampicillin, and ciclacillin, have largely similar antibacterial spectra, exhibiting activity against both penicillin sensitive gram-positive and gram-negative microorganisms. The susceptibility of ampicillin or amoxicillin to -lactamase may be overcome by combination with a P-lactamase inhibitor. Clavulanic acid and sulbactam ate two such P-lactamase inhibitors in clinical use. The products Augmentin, a combination of clavulanic acid and amoxycillin for oral use primarily, and Unasyn, a combination of sulbactam and ampicillin for use by injection, ate highly active against both gram-positive aerobic and anaerobic organisms in addition to many important gram-negative pathogens. Carbenicillin and ticarcillin possess moderate broad-spectmm activity and were the first penicillins to show activity against Pseudomonas species. Aziocillin, mezlocillin, and piperacillin possess largely the same characteristics but have slightly greater potency against many gram-negative species. Temocillin is the first penicillin to possess a high level of activity against gram-negative organisms, notably the Pnterobacteriaceae as well as excellent P-lactamase stability. The introduction of the 6oc-metho>y group and the concomitant -lactamase stability compromises activity against both gram-positive organisms and Pseudomonas species. Similarly BRL 36650, having the 6a-formamido substituent, exhibits high bacterial P-lactamase stability. Some activity is retained against most species of Streptococci but the compound is inactive against Staphylococci. BRL 36650 is highly potent against most gram-negative organisms including refractory gram-negative species such as Jicinetobacter emA Pseudomonas. The level of potency is much greater than either that of ticarcillin or piperacillin (56).  [c.83]

Clindamycin has found use in the treatment of common infections caused by gram-positive cocci It is also efficacious in the treatment of anaerobic infections, including actinomycosis (38). Clindamycin has been shown to be active against strains of P/asmodiumin animals (66—68).  [c.89]

Malaria is transmitted by the bite of an infected female Anopheles mosquito, one of the few species of the insect capable of carrying the human malaria parasite. The responsible protozoa ate from the genus P/asmodium of which only four of some 100 species can cause the disease in humans. The remaining species affect rodents, reptiles, monkeys, birds, and Hvestock. The species that infect humans are P/asmodium falciparum Plasmodium vivax Plasmodium malariae and Plasmodium ovale. Note that concomitant multiple malaria infections are commonly seen in endemic areas, a phenomenon that further compHcates choice of treatment.  [c.270]

Camera de la Industria Quimica y Petroquimica de Aigentina (CIQYP)  [c.255]

Ave. Leandro N. Alem 1067, piso 14-(1001) Buenos Ahes, Aigentina  [c.255]

See pages that mention the term M AZOMETHANE : [c.249]    [c.267]    [c.274]    [c.74]    [c.78]    [c.474]    [c.229]    [c.468]    [c.254]    [c.85]    [c.521]    [c.531]    [c.172]    [c.242]    [c.503]    [c.673]    [c.673]    [c.682]    [c.685]    [c.686]    [c.686]    [c.692]    [c.695]    [c.695]    [c.697]    [c.784]    [c.811]    [c.812]    [c.822]    [c.28]    [c.141]    [c.141]    [c.141]    [c.141]    [c.255]    [c.255]    [c.212]    [c.18]    [c.29]    [c.49]    [c.50]   
See chapters in:

Organic syntheses Biclormethyl ether  -> M AZOMETHANE